Business Insight & People News
Biological Products, (No Diagnostic Substances)
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Philip Astley-Sparke | Executive Chairman | 20,000 | $36.4K | — position reported |
We hold no Form 4 transaction rows for enGene Therapeutics Inc. yet. An insider report can exist without any transaction rows we could parse, so an empty table here means “we have nothing to show you”, not “nothing happened”.
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
The report an officer, director or large shareholder must file after trading their own company’s stock.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together. 2 of the positions below were reported on filings shared by several filers at once.
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Forbion Growth Management B.V. | TenPercentOwner | 6,798,362 joint | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | TenPercentOwner | 6,798,362 joint | |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | TenPercentOwner | 3,036,153 |
See the full ownership map — every entity that files as an owner of a US public company.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
enGene Therapeutics Inc.’s own filings and multiplied by our closing price.
Full method.
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from enGene Therapeutics Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.